SATuRN output: reports, clinical cases & publications

Here we provide you with HIV & TB drug resistance information in the form of reports, clinical cases, tweets and publications.
In this new section of the bioafrica.net website, physicians, researchers and public health officials can learn about our drug resistance work and its application to the management of patients failing ARVs and anti-TB therapies.

Reports


SATuRN Collaborates on a Successful Molecular Diagnostics in HIV/AIDS and Tuberculosis in Zimbabwe, 6-9 Aug 2013

By Justen Manasa - 2013-08-21
SATuRN 2013 report


SATuRN and Khethimpilo HIV Drug Resistance and Clinical Management Workshop Report, Durban, 11-12 July 2013

By Dean Solomon and Tulio de Oliveira - 2013-08-01
SATuRN 2013 report


Major data analysis determines the trends of HIV-1 drug resistance mutations in South Africa.

By Tulio de Oliveira - 2013-07-01
SATuRN report 2013


Transferring knowledge and skills to frontline medical personnel fighting the HIV & TB epidemics in rural South Africa

By Tulio de Oliveira, Justen Manasa, Richard Lessells - 2013-03-16
SATuRN 2013 report


Bioafrica.net & SATuRN webpages received 186,746 visits in the past 12 months!

By Tulio de Oliveira - 2013-02-26
SATuRN 2013 report


Clinical Case Study: The Diagnosis and Management of First-line Antiretroviral Treatment Failure

By Theresa Rossouw, Tulio de Oliveira & Richard Lessells - 2013-01-16
SATuRN 2012 report


2nd Nurses and Health Care Workers Drug Resistance Training for the scale-up of resistance testing in the Free State Province, South Africa

By Dominique Goedhals & Cloete van Vuuren - 2012-07-10
SATuRN 2012 report

SATuRN output, 15 minutes, All reports...

Clinical Cases

HIV Case 1 - Adult female with virological failure on first line d4T/3TC/EFV
HIV Case 2 - Adult female patient with virological failure on first line therapy after substitution of EFV to NVP
HIV Case 3 - Adult female patient on treatment for epilepsy with virological failure on TDF/3TC/EFV; previous single dose NVP for PMTCT
HIV Case 4 - Adult female patient with virological and immunological failure after treatment interruption for symptomatic hyperlactataemia
HIV Case 5 - Adolescent initiated on first line therapy of d4T/3TC/EFV with virological and immunological failure
HIV Case 6 - Adult male patient with adverse effects and multiple ARV treatment switches. No virological response to LPV/r based second line therapy
HIV Case 7 - Adolescent case with adherence and toxicity problems
HIV Case 8 - Adult patient initiated on first line d4T/3TC/EFV with low CD4+ cell count (34 cells/ul) and concurrent TB treatment

Publications

Moderate to high levels of pre-treatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses (2019), I.F.:4

Early detection of emergent extensively drug resistant tuberculosis (XDR-TB) by flow cytometry-based phenotyping and whole genome sequencing. Antimicrob Agents Chemother. (2019), I.F.:4.476

Spatial structure of depression in South Africa: A longitudinal panel survey of a nationally representative sample of households. Scientific Reports (2019), I.F.:4.122

Sociobehavioral and community predictors of unsuppressed HIV viral load: multilevel results from a hyperendemic rural South African population. AIDS (2019), I.F.:4.914

Genome Detective: An Automated System for Virus Identification from High-throughput sequencing data.. Bioinformatics (2018), I.F.:7.307

High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. J Epidemiol Community Health (2018), I.F.:3.608

Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV (2018), I.F.:9.842

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet ID (2018), I.F.:19.864

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest. (2018), I.F.:12.784

Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science (2018), I.F.:37.205

SATuRN output,15 minutes, All publications...